← Back to patent-cliff list
5-aminolevulinic acid hydrochloride/Sodium ferrous citrate
Tier C — Watch / trade5-aminolevulinic acid hydrochloride/Sodium ferrous citrate
Sbi Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Indications (approved)：肾毒性, Anaemia, COVID-19, Type 2 diabetes
Regional status
US
-
EU
-
China
-
Japan
Phase II
2014-01-10
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 5-aminolevulinic acid hydrochloride/Sodium ferrous citrate?
Approved indications include: 肾毒性, Anaemia, COVID-19, Type 2 diabetes.
When does the 5-aminolevulinic acid hydrochloride/Sodium ferrous citrate patent expire?
No public expiry year is available for 5-aminolevulinic acid hydrochloride/Sodium ferrous citrate yet; this page updates once verified.
How do I get a quote for 5-aminolevulinic acid hydrochloride/Sodium ferrous citrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-12